BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Kowa Pharmaceuticals America 

5331 Perimeter Parkway Court

Montgomery  Alabama  36116  U.S.A.
Phone: 334-288-1288 Fax: 334-288-2788


SEARCH JOBS




Industry
Pharmaceutical






 Company News
Kowa Pharmaceuticals America Release: Data Showed After 52 Weeks, LIVALO® (Pitavastatin) 4 Mg Maintained Similar Safety And Significantly Greater LDL-C Reduction Compared With Pravastatin 40 Mg In HIV-Infected Adults With Dyslipidemia 5/1/2014 8:57:52 AM
Amarin Corporation PLC (AMRN) And Kowa Pharmaceuticals America Announce U.S. Co-Promotion Agreement For Vascepa® (Icosapent Ethyl) Capsules 4/1/2014 11:05:15 AM
Kowa Pharmaceuticals America Release: New Data Showed LIVALO® (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1c Levels in HIV-infected Adults with Dyslipidemia 6/17/2013 11:46:12 AM
Kowa Pharmaceuticals America Release: New Superiority Trial Showed LIVALO® (Pitavastatin) 4 mg Provided Significantly Greater LDL-C Reduction in HIV-Infected Adults With Dyslipidemia Versus Pravastatin 40 mg 3/7/2013 10:21:35 AM
Kowa Pharmaceuticals America, Eli Lilly and Company (LLY) Release Results From a Pharmacokinetic Study 7/23/2012 7:54:22 AM
John O'Hurley Teams Up With the National Lipid Association, Kowa Pharmaceuticals America and Eli Lilly and Company (LLY) to Announce Results of Landmark Statin USAGE Survey, Largest Known Survey of Cholesterol Patients 6/19/2012 9:06:23 AM
Eli Lilly and Company (LLY) and Kowa Pharmaceuticals America Reveal Positive Results of PREVAIL US Study 5/31/2012 7:33:36 AM
Kowa Pharmaceuticals America Release: New Study Data Published Assessing the Effect of LIVALO(R) vs. Crestor(R) on International Normalized Ratio on Steady-State Warfarin 2/13/2012 9:53:49 AM
Kowa Pharmaceuticals America Release: New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy 7/18/2011 5:59:10 AM
Cipher Pharmaceuticals (DND.TO) Achieves Sales Milestone For Lipofen(R); Triggering $1 Million From Kowa Pharmaceuticals America 7/7/2010 7:13:26 AM
12